Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of C-10355 and C-10358 in Healthy Volunteers
NCT02392702Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Mar 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deutivacaftor in cystic fibrosis (CF) (6 arms), sponsored by Concert Pharmaceuticals. Primary endpoints: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 24 hours and Pharmacokinetic Profile at 96 hours. Started Mar 2015; status: completed.
02
Drugs
deutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02392702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392702.